Stocks & Financial News
Breaking financial news 24/7 courtesy of TradingCharts.com Inc. / TFC Commodity Charts
CORCEPT THERAPEUTICS is Being Investigated for Potential Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLP
CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION
If you are a Corcept investor and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing mail@kaplanfox.com or dhall@kaplanfox.com, or by calling (800) 290-1952.
On December 31, 2025, before markets opened, Corcept announced in a press release that the “U.S. Food and Drug Administration (FDA or the Agency) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism.” The Company stated in the press release that “the Agency concluded it could not arrive at a favorable benefit-risk assessment for relacorilant without Corcept providing additional evidence of effectiveness.”
Following this news, the price of Corcept stock has fallen more than $37 per share, over 50%, during intraday trading on December 31, 2025.
WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
If you have any questions about this investigation, please contact:
CONTACT:
Donald R. Hall
KAPLAN FOX & KILSHEIMER LLP
800 Third Avenue, 38th Floor
New York, New York10022
(212) 687-1980
dhall@kaplanfox.com
Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Street, Suite 1501
Oakland, California 94612
(415) 772-4704
lking@kaplanfox.com
Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.
https://www.kaplanfox.com/case/corcept-therapeutics-inc/
View the original release on www.newmediawire.com
COMTEX_471810764/2549/2026-01-05T13:04:53